




Company description

Formycon is a leading and independent developer of high-quality biopharmaceutical medicines, especially biosimilars. These are follow-on versions of biopharmaceuticals, for which exclusivity has expired. Formycon focuses on treatments in ophthalmology, immunology and on other key chronic diseases and currently has four biosimilars in development. Because of their size and structural complexity, and their production using living cell systems, biosimilars require very significant time, effort and expertise, both in their development and in their subsequent production. Formycon's activities span the entire range from technical-pharmaceutical development to clinical trials, all way through to preparation of dossiers for regulatory approval. Based on the clinically validated experience with antibodies and antibody fusion proteins, the company initiated the development of a COVID-19 fusion protein (FYB207) in March 2020, shortly after the COVID-19 pandemic broke out in Europe.

Development pipeline



Strategy and goals

Formycon is specifically concentrating on the third and fourth wave of biosimilars. The company has licensed out its late stage biosimilars in ophthalmology FYB201 and FYB203. Commercialization partners for FYB201 are Coherus BioSciences, Inc. (US) and Teva Pharmaceutical Industries Ltd. (EU plus). FYB202 is being developed in a joint venture with Aristo Pharma in which Formycon has a 24,9 % stake. The Formycon Group is currently focusing on research and development activities for both, its own and out-licensed biosimilar projects. Development operation for the partnered projects are the current source of its revenues. After successful approval of the biosimilar candidates, Formycon is entitled to participate in the subsequent marketing revenues either via royalties or a direct participation. With this upside Formycon has significant growth potential and a unique and leading position in the rapidly evolving biosimilar market space.





Facts

Founded: 2012

Headquarters: Planegg / Munich

Employees: > 160

Management

Dr. Carsten Brockmeyer (CEO) Dr. Nicolas Combé (CFO) Dr. Stefan Glombitza (COO)

Supervisory Board

Dr. Olaf Stiller (Chairman)

Peter Wendeln (Deputy Chairman)

Klaus Röhrig (Member Supervisory Board)

$\textbf{Key financials} \ (\text{in} \in \text{million})$

2017	2018	2019	2020
29,4	43,0	33,2	34,2
-1,5	7,1	-1,4	-4,8
-1,6	7,1	-2,3	-5,9
82,9	83,9	90,0	90,0
	29,4 -1,5 -1,6	29,4 43,0 -1,5 7,1 -1,6 7,1	29,4 43,0 33,2 -1,5 7,1 -1,4 -1,6 7,1 -2,3

Financial calendar

November 2021

Statement Nine-Month Figures 2021

September 27, 2021

Annual General Meeting 2021

September 21, 2021

Publication of Half-Year Report 2021

June 2021

Statement Q1/2021

May 17, 2021

Publication of Annual Report 2020

Market data

ISIN: DF000A1FWVY8

Market Segment: Frankfurt, Stock Exchange "Scale"

Market Capitalization: \sim \in 670 million Outstanding Shares: 11.046.500

Shareholder Structure

15 % Institutional Investors

35% Family Offices

15 % Founders and Management

35% Free Float

Extract press releases 2021

September 2021

Formycon's COVID-19 drug FYB207 wins prestigious Pharma Trend Image & Innovation Award 2021

August 2021

Formycon reports on the status of FYB207 development

August 2021

Formycon and Bioeq announce submission of the biologics license application (BLA) for FYB201, a biosimilar candidate to Lucentis(R)1 (ranibizumab) to the U.S. Food and Drug Administration (FDA)

July 2021

Formycon receives Euro 12.7 million grant for further development of COVID-19 drug FYB207 as part of the Bavarian Therapy Strategy to combat the COVID-19 pandemic

June 202⁴

Formycon Reports Financial Results for the First Quarter of 2021

Read more



Strategy and goals

Through their proven efficacy, cost efficiency and high standard of quality, biosimilar medicines are already making a major contribution towards enabling patient access to effective medical treatments. With its biosimilars, Formycon will help not only patients around the world but also contributes to ease the financial strains on the world's healthcare systems. Starting with FYB206, an undisclosed and fully owned biosimilar candidate, Formycon aims to apply a clear growth strategy by maintaining a higher ownership stake and therefore pipeline value within any future partnering constellation. With FYB207, an innovative project outside the biosimilar space, Formycon has in addition set up a very promising project for the treatment of COVID-19 that is planned to enter clinical development in the first half of 2022.

Contact

Sabrina Müller | Corporate Communications & Investor Relations +49 89 86 46 67 149 | sabrina.mueller@formycon.com

This document may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approvals process, the timing of the controls of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patient litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other quarantees that the products will receive the necessary regulatory approvals or that they will provide exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscrible for securities of Formycon AG. No public offering of securities of Formycon AG assumes no adjust the made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.